Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
Department of Surgery, University of Cincinnati, Cincinnati, Ohio; Department of Otolaryngology, University of Cincinnati, Cincinnati, Ohio.
J Surg Res. 2022 Sep;277:261-268. doi: 10.1016/j.jss.2022.04.003. Epub 2022 May 4.
Tertiary hyperparathyroidism (3HPT) is observed in up to 40% of renal transplant patients. Standard guidelines defining 3HPT and indications for operative intervention are not well described.
We conducted a retrospective, single-institution cohort study of patients who underwent renal transplant between January 1, 2012 and January 30, 2018, with a minimum of 13-month follow-up and at least 1 y of allograft function. We defined 3HPT as having elevated serum level parathyroid hormone (>88 pg/mL) after successful renal transplantation or multiple instances of elevated serum calcium starting at least 3 mo after transplant. We compared graft failure rates after stratifying the cohort based on management strategy: expectant, medical management with cinacalcet, and parathyroidectomy.
Out of the 381 transplanted patients with functional grafts at 1 y, 178 patients (46.6%) were found to have 3HPT. One hundred twenty-nine patients (72.5%) were managed expectantly without medications, 35 patients (19.7%) were managed medically, and 14 patients (7.8%) were managed with parathyroidectomy. Twenty-two patients (17.1%) in the observation group had graft failure, 4 patients (11.4%) in the medically managed group had graft failure, and 0 patients in the surgery group had graft failure. Surgical intervention was associated with decreased renal allograft failure when compared to the combined cohort of nonoperative 3HPT patients (P = 0.03). All patients who underwent parathyroidectomy were cured and did not have graft failure as of December 30, 2019. Calcium elevation, but not PTH elevation, was associated with referral for parathyroidectomy on multivariable logistic regression analysis (P < 0.01).
At our institution, the referral rate for parathyroidectomy among patients with 3HPT remains low. Parathyroidectomy was associated with high cure rates and reduced graft failure. Surgery may be underutilized in the management of 3HPT.
三级甲状旁腺功能亢进症(3HPT)在多达 40%的肾移植患者中可见。目前并未很好地描述定义 3HPT 和手术干预指征的标准指南。
我们进行了一项回顾性单机构队列研究,纳入 2012 年 1 月 1 日至 2018 年 1 月 30 日期间接受肾移植的患者,这些患者的随访时间至少为 13 个月,且移植物功能至少持续 1 年。我们将术后成功的肾移植或在移植后至少 3 个月多次出现血清钙升高的患者定义为甲状旁腺激素水平升高(>88 pg/mL),将其诊断为 3HPT。我们根据管理策略对患者进行分层,比较各组的移植物失功率:期待治疗、使用西那卡塞进行药物治疗和甲状旁腺切除术。
在 381 例术后 1 年有功能移植物的移植患者中,有 178 例(46.6%)患者被诊断为 3HPT。129 例(72.5%)患者未接受药物治疗,仅接受期待治疗,35 例(19.7%)患者接受药物治疗,14 例(7.8%)患者接受甲状旁腺切除术。在观察组中,有 22 例(17.1%)患者发生移植物失功,在药物治疗组中,有 4 例(11.4%)患者发生移植物失功,而在手术组中,无患者发生移植物失功。与非手术治疗 3HPT 患者的综合队列相比,手术干预与降低肾移植失功风险相关(P=0.03)。截至 2019 年 12 月 30 日,所有接受甲状旁腺切除术的患者均被治愈,且未发生移植物失功。多变量逻辑回归分析显示,只有血钙升高,而甲状旁腺激素升高与甲状旁腺切除术无关(P<0.01)。
在本机构,3HPT 患者接受甲状旁腺切除术的转诊率仍然较低。甲状旁腺切除术可获得较高的治愈率并降低移植物失功风险。在 3HPT 的治疗中,手术可能未得到充分利用。